mRNA Cancer Vaccines.

Area of Science:

• Oncology
• Immunology
• Vaccinology

Background:

• Messenger RNA (mRNA) vaccines represent a novel class of vaccines with a strong safety profile and adaptable manufacturing.
• Their application in oncology is rapidly evolving, showing promise in preclinical and clinical settings.

Purpose of the Study:

• To review the preclinical and clinical data of mRNA-based cancer vaccine approaches.
• To explore the diverse applications of mRNA technology in cancer immunotherapy.

Main Methods:

• Utilizing mRNA to encode tumor-associated antigens (TAAs) for direct patient immunization.
• Developing personalized mRNA vaccines targeting patient-specific neoantigens.
• Employing mRNA for in vitro transfection of patient-derived cells for adoptive immunotherapy.

Main Results:

• RNActive® technology demonstrates balanced immune responses in animal models and is in clinical trials.
• Personalized neoantigen vaccines can be rapidly produced by analyzing tumor exomes.
• mRNA-transfected dendritic cells and T cells show potential in cellular therapies.

Conclusions:

• mRNA technology provides a versatile platform for developing both general and personalized cancer vaccines.
• mRNA-based cellular therapies, including engineered dendritic cells and T cells, are promising avenues for cancer treatment.
• Further clinical evaluation is ongoing to establish the efficacy of these mRNA-based immunotherapeutic strategies.